By: fernando pessoa
There are 14 publications on figitumumab by Antonio Gualberto. http://www.ncbi.nlm.nih.gov/pubmed/?term=figitumumab%20Gualberto Two have been retracted. One of the 14 is a retration notice, but how...
View ArticleBy: M
Adam and Ivan, I have though for some time as I have read Retraction Watch, what is the follow on effect of retractions (such as these) on the patent applications/patents that correspond to or have...
View ArticleBy: DME
M, I am not a patent person – but I am a scientist involved in the biopharm industry – but if these retractions are regarding clinical trials, then I wouldn’t think that it would have much to do with...
View ArticleBy: puzzled monkey (Conrad T Seitz MD)
Great answer, DME: I think that fact nullifies any repercussions for a substance’s patent.
View ArticleBy: fernando pessoa
Who know what the patents are about? This issue is also about other clinical trials. I do understand that some papers are not about clinical trials. The fact is that the molecule does not work in...
View Article
